Harith Rajagopalan - 30 Jan 2025 Form 4 Insider Report for FRACTYL HEALTH, INC. (GUTS)

Role
Chief Executive Officer, Director
Signature
/s/ Lisa A. Davidson, Attorney-in-fact
Issuer symbol
GUTS
Transactions as of
30 Jan 2025
Net transactions value
-$15,739
Form type
4
Filing time
03 Feb 2025, 18:04:37 UTC
Previous filing
13 Nov 2024
Next filing
03 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GUTS Common Stock Options Exercise $35,612 +20,948 +4.3% $1.70 512,277 30 Jan 2025 Direct
transaction GUTS Common Stock Sale $40,798 -20,948 -4.1% $1.95 491,329 30 Jan 2025 Direct F1, F2
transaction GUTS Common Stock Options Exercise $154,652 +90,972 +19% $1.70 582,301 31 Jan 2025 Direct
transaction GUTS Common Stock Sale $165,205 -90,972 -16% $1.82 491,329 31 Jan 2025 Direct F1, F3
holding GUTS Common Stock 292,171 30 Jan 2025 By 2021 Irrevocable Trust
holding GUTS Common Stock 292,170 30 Jan 2025 By 2016 Irrevocable Trust
holding GUTS Common Stock 18,639 30 Jan 2025 By 2021 Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GUTS Stock Option Options Exercise $0 -20,948 -17% $0.000000 102,536 30 Jan 2025 Common Stock 20,948 $1.70 Direct F4
transaction GUTS Stock Option Options Exercise $0 -90,972 -89% $0.000000 11,564 31 Jan 2025 Common Stock 90,972 $1.70 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents sales pursuant to a Rule 10b5-1 plan that the Reporting Person entered into on September 12, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.9100 to $2.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.8000 to $1.8800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The option is fully vested and exercisable.